Patients suffering from inflammatory bowel diseases, such as ulcerative rectocolitis and crohn’s disease, rely on multiple medications throughout their life to treat symptoms, prevent relapses, promote healing and prevent urgent surgical intervention. current drugs are not specifically targeted for the bowels and do not promote definitive healing, which may prolong the treatment and cause a variety of side effects in patients.
The compounds developed here enable patients with inflammatory bowel diseases to be treated with nanoparticles that promote the release of drugs specifically in the intestines, potentiating their anti-inflammatory action through longer retention time and availability. drug- carrying nanoparticles provide better anti-inflammatory effects than the options currently available on the market and enable improvements in the patient’s quality of life.
Agência Unesp de Inovação
Tel: +55 11 5627.0696
Daniele Martins de Lima